3 In the STEP-1 trial of semaglutide for the treatment of obesity, secondary findings showed improvements in the GLP-1 treatment group in systolic blood pressure (-6.16mm Hg) and diastolic blood pressure (-2.83mm Hg)
Most short-term studies (812 weeks) show mild or no side effects, but chronic use safety requires ongoing medical supervision
Complementary Research Compounds for Broader Metabolic Research Design Retatrutide's triple-agonist mechanism engages GLP-1, GIP, and glucagon receptors, but the broader biology of metabolic dysfunction extends beyond the receptors Retatrutide directly activates
Have a look down, there are some products examples: [1]
Participants were trained in handling the pen injector when dispensed for the first time, they continued, and instructed to inject the trial product subcutaneous once-weekly in the abdomen or thigh
A healthcare provider should pinch the skin to create a fold before injection and inject at a 45-90 degree angle depending on tissue availability